Schilling, Bastian 1979-
Bastian Schilling researcher ORCID ID = 0000-0001-8859-4103
VIAF ID: 139160076 (Personal)
Permalink: http://viaf.org/viaf/139160076
Preferred Forms
4xx's: Alternate Name Forms (1)
5xx's: Related Names (3)
- 551 _ _ ‡a Dortmund ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Universitätsklinikum Essen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universitätsklinikum Würzburg ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma | |
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification | |
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma | |
Effects of Label Noise on Deep Learning-Based Skin Cancer Classification | |
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma | |
Long‑Term Outcomes in BRAF‑Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure? | |
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG | |
Model soups improve performance of dermoscopic skin cancer classifiers | |
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) | |
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy | |
Skin cancer classification via convolutional neural networks systematic review of studies involving human experts | |
Suppression der LPS- und Zymosan A-induzierten Immunantwort von Makrophagen durch zerstörte Muskelzellen in vitro | |
transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression |